Helsinn Group, a global pharmaceutical company specialising in oncology and Chugai Pharma Europe, a research-based pharmaceutical organisation, have renewed a distribution and license agreement.
The partnership will aim to further commercialise Akynzeo in the UK and Ireland for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.
Akynzeo, a combination of netupitant and palonosetron, could mitigate the effects of CINV in many in this region, offering respite from the negative effects of chemotherapy.
Managing Director at Chugai Pharma Europe, Troy Robinson, commented: “Oncology remains an important pillar of our business. The joint effort we are making with Helsinn will ensure that we continue to support patients in the UK and Ireland throughout their cancer journey.”
Helsinn Group CEO, Dr Melania Rolli, commented: “Our shared vision, values and dedication to supportive care will continue to fuel our collective journey in enhancing the quality of life for cancer patients in this crucial market.”
